These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 37802570)
1. In vitro methods to assess 11β-hydroxysteroid dehydrogenase type 2 activity. Kley M; Moser SO; Winter DV; Odermatt A Methods Enzymol; 2023; 689():167-200. PubMed ID: 37802570 [TBL] [Abstract][Full Text] [Related]
2. Species-specific differences in the inhibition of 11β-hydroxysteroid dehydrogenase 2 by itraconazole and posaconazole. Inderbinen SG; Zogg M; Kley M; Smieško M; Odermatt A Toxicol Appl Pharmacol; 2021 Feb; 412():115387. PubMed ID: 33387577 [TBL] [Abstract][Full Text] [Related]
3. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. Atanasov AG; Ignatova ID; Nashev LG; Dick B; Ferrari P; Frey FJ; Odermatt A J Am Soc Nephrol; 2007 Apr; 18(4):1262-70. PubMed ID: 17314322 [TBL] [Abstract][Full Text] [Related]
4. Apparent mineralocorticoid excess syndrome: an overview. Palermo M; Quinkler M; Stewart PM Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):687-96. PubMed ID: 15761540 [TBL] [Abstract][Full Text] [Related]
5. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess. Whorwood CB; Stewart PM J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678 [TBL] [Abstract][Full Text] [Related]
6. [From gene to disease; 'apparent mineralocorticoid excess' syndrome, a syndrome with an apparent excess of mineral corticoids]. Levtchenko EN; Deinum J; Knoers NV; Hermus AR; Monnens LA; Lenders JW Ned Tijdschr Geneeskd; 2007 Mar; 151(12):692-4. PubMed ID: 17447595 [TBL] [Abstract][Full Text] [Related]
7. Prenatal overexposure to glucocorticoids programs renal 11β-hydroxysteroid dehydrogenase type 2 expression and salt-sensitive hypertension in the rat. Tang JI; Kenyon CJ; Seckl JR; Nyirenda MJ J Hypertens; 2011 Feb; 29(2):282-9. PubMed ID: 21045727 [TBL] [Abstract][Full Text] [Related]
8. Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature. Adamidis A; Cantas-Orsdemir S; Tsirka A; Abbott MA; Visintainer P; Tonyushkina K Pediatr Endocrinol Rev; 2019 Mar; 16(3):335-358. PubMed ID: 30888125 [TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals. Beck KR; Telisman L; van Koppen CJ; Thompson GR; Odermatt A J Steroid Biochem Mol Biol; 2020 May; 199():105605. PubMed ID: 31982514 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole. Beck KR; Bächler M; Vuorinen A; Wagner S; Akram M; Griesser U; Temml V; Klusonova P; Yamaguchi H; Schuster D; Odermatt A Biochem Pharmacol; 2017 Apr; 130():93-103. PubMed ID: 28131847 [TBL] [Abstract][Full Text] [Related]
11. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. Li A; Li KX; Marui S; Krozowski ZS; Batista MC; Whorwood CB; Arnhold IJ; Shackleton CH; Mendonca BB; Stewart PM J Hypertens; 1997 Dec; 15(12 Pt 1):1397-402. PubMed ID: 9431844 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in the study of 11β-Hydroxysteroid dehydrogenase type 2 (11β-HSD2)Inhibitors. Zhou C; Ye F; Wu H; Ye H; Chen Q Environ Toxicol Pharmacol; 2017 Jun; 52():47-53. PubMed ID: 28366868 [TBL] [Abstract][Full Text] [Related]
13. 11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension. Campino C; Carvajal CA; Cornejo J; San Martín B; Olivieri O; Guidi G; Faccini G; Pasini F; Sateler J; Baudrand R; Mosso L; Owen GI; Kalergis AM; Padilla O; Fardella CE Endocrine; 2010 Feb; 37(1):106-14. PubMed ID: 19882252 [TBL] [Abstract][Full Text] [Related]
14. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. Li A; Tedde R; Krozowski ZS; Pala A; Li KX; Shackleton CH; Mantero F; Palermo M; Stewart PM Am J Hum Genet; 1998 Aug; 63(2):370-9. PubMed ID: 9683587 [TBL] [Abstract][Full Text] [Related]
15. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Stewart PM Eur J Endocrinol; 2003 Sep; 149(3):163-8. PubMed ID: 12943516 [TBL] [Abstract][Full Text] [Related]
16. 11β-HSD2 SUMOylation Modulates Cortisol-Induced Mineralocorticoid Receptor Nuclear Translocation Independently of Effects on Transactivation. Jiménez-Canino R; Lorenzo-Díaz F; Odermatt A; Bailey MA; Livingstone DEW; Jaisser F; Farman N; Alvarez de la Rosa D Endocrinology; 2017 Nov; 158(11):4047-4063. PubMed ID: 28938454 [TBL] [Abstract][Full Text] [Related]
17. Cortisol metabolism in hypertension. Hammer F; Stewart PM Best Pract Res Clin Endocrinol Metab; 2006 Sep; 20(3):337-53. PubMed ID: 16980198 [TBL] [Abstract][Full Text] [Related]
18. Environmental inhibitors of 11β-hydroxysteroid dehydrogenase type 2. Ma X; Lian QQ; Dong Q; Ge RS Toxicology; 2011 Jul; 285(3):83-9. PubMed ID: 21515335 [TBL] [Abstract][Full Text] [Related]
19. The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. Krozowski Z; Li KX; Koyama K; Smith RE; Obeyesekere VR; Stein-Oakley A; Sasano H; Coulter C; Cole T; Sheppard KE J Steroid Biochem Mol Biol; 1999; 69(1-6):391-401. PubMed ID: 10419017 [TBL] [Abstract][Full Text] [Related]
20. 11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension. Hatakeyama H; Inaba S; Miyamori I Hypertension; 1999 May; 33(5):1179-84. PubMed ID: 10334808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]